Cross reactive CTL responses in persons infected with different HIV viral clades. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Cross reactive CTL responses in persons infected with different HIV viral clades.

Conf Adv AIDS Vaccine Dev. 1997 May 4-7;:43. Unique Identifier : AIDSLINE MED/97927029
Gotch F; McAdam S; Whitworth J; Charing Cross & Westminster Medical School, Dept. Immunology, Chelsea; & Westminster Hospital, London, United Kingdom. Fax: 181-746-5997.

Abstract: 8,500 persons/day are infected with HIV, 90% of whom live in developing countries. It would cost 300 billion dollars to treat all HIV infected individuals in the world with modern, potent, antiretroviral drugs. This is clearly not feasible and there is an urgent need to develop a vaccine for HIV. Such a prophylactic vaccine will need to be effective and safe; and to induce cross-reactive immune responses in order to protect at-risk individuals from infection or from disease progression with all the different subtypes or clades of virus to which they may be exposed. There is an increasing body of evidence to suggest that cytotoxic T-lymphocytes play a crucial role in the control of HIV throughout infection, and may be able to offer some degree of protection. We propose therefore that a vaccine for HIV should generate high levels of virus specific CTL prior to virus exposure. We have conducted experiments to measure gag-specific cross-clade-reactive CTL activity in infected persons from the Gambia, Uganda and the UK. Our preliminary results have enabled us to evaluate whether a vaccine based on a single well-characterised clade of virus (B clade) would be expected to induce sufficient cross-reactive cellular immune responses to offer protection from infection with other clades of HIV.1 such as A, C and D clade which predominate in Sub-Saharan Africa where vaccines are most urgently needed.
Keywords: *HIV/GENETICS *HIV Infections/IMMUNOLOGY *T-Lymphocytes, Cytotoxic/IMMUNOLOGYKWDhiv/geneticsKWDhivinfections/immunologyKWDt-lymphocytes,cytotoxic/immunology
971130
M97B1192

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .